Cambiar Aggressive Value ETF
CAMX

$29.21

0.18%

Market Cap: $57.5M

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

15% more capital invested

Capital invested by funds: $5.4M [Q1] → $6.23M (+$828K) [Q2]

1.49% more ownership

Funds ownership: 9.32% [Q1] → 10.8% (+1.49%) [Q2]

0% more funds holding

Funds holding: 9 [Q1] → 9 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CAMX.

See Analyst Rankings

Financial journalist opinion

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1 ≤ 1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom and quality of life scores vs baseline Study results reinforce previously reported interim results from ACROINNOVA 21 LUND, Sweden , July 15, 2024 /PRNewswire/ -- Camurus (NASDAQ: CAMX) (STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836) study, which evaluated safety and efficacy of the company's once-monthly octreotide subcutaneous (SC) depot (CAM2029). The study included a total of 135 patients with acromegaly who were biochemically controlled (IGF-1≤1xULN) or uncontrolled on stable doses of standard-of-care (SoC) with first generation somatostatin ligands (SRL) at screening; of these, 81 were new to study patients and 54 were roll-over patients from 24-week randomized treatment with octreotide SC depot or placebo (ACROINNOVA 1).

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

See News Rankings